Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21241061 | 0.80 | CYP1A2 (0.34) | GABRA1GABRB2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1106716 | 0.77 | — | — | |
| SCHEMBL14350774 | 0.76 | ALDH1A1 (0.41) | CYP1A2CYP2C9 | |
| SCHEMBL50976 | 0.74 | ALDH1A1 (0.38) | CYP1A2CYP2C9 | |
| SCHEMBL26340785 | 0.69 | ALOX15 (0.48) | GABRA1GABRB2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL173206 | 0.67 | — | — | |
| SCHEMBL10110590 | 0.65 | HSPA5 (0.34) | GABRA1GABRB2 | |
| SCHEMBL31464904 | 0.65 | NQO1 (0.34) | — | |
| SCHEMBL426079 | 0.64 | — | — | |
| SCHEMBL9944594 | 0.64 | KDM4E (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-9777024-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2017-10-03 | — | — | US | disclosed |
| US-9670150-B2 | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators | ALLERGAN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160333043-A1 | E-Selectin Antagonists Modified By Macrocycle Formation to the Galactose | GLYCOMIMETICS, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160137672-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2016-05-19 | — | — | US | disclosed |
| US-9221843-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150119362-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2015-04-30 | — | — | US | disclosed |
| US-20130274230-A1 | (2-UREIDOACETAMIDO)ALKYL DERIVATIVES AS FORMYL PEPTIDE RECEPTOR 2 MODULATORS | ALLERGAN, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130018049-A1 | Azaindole Compounds and Methods for Treating HIV | GLAXOSMITHKLINE LLC (US) | 2013-01-17 | — | — | US | disclosed |
| US-20120149743-A9 | Selenophene and Selenazole Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC (US) | 2012-06-14 | — | — | US | disclosed |
| US-20110275683-A1 | Selenophene and Selenazole Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274230-A1 | (2-UREIDOACETAMIDO)ALKYL DERIVATIVES AS FORMYL PEPTIDE RECEPTOR 2 MODULATORS | FPR2, FPR3, FPR1 | GABRA1 553/4885GABRB2 350/4885CYP1A2 3093/4885 |
| US-20150119362-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | GABRA1 2654/4885GABRB2 2115/4885CYP1A2 735/4885 |
| US-20160333043-A1 | E-Selectin Antagonists Modified By Macrocycle Formation to the Galactose | SELE, SELPLG, SELL | GABRA1 2606/4885GABRB2 2989/4885CYP1A2 2272/4885 |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | GABRA1 3234/4885GABRB2 2863/4885CYP1A2 848/4885 |
| US-20110275683-A1 | Selenophene and Selenazole Carboxylic Acid Derivatives | DAO, DDO, SELENOI | GABRA1 1035/4885GABRB2 682/4885CYP1A2 437/4885 |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | GABRA1 3234/4885GABRB2 2863/4885CYP1A2 848/4885 |
| US-20130018049-A1 | Azaindole Compounds and Methods for Treating HIV | AZI2, TPMT, INMT | GABRA1 1781/4885GABRB2 2360/4885CYP1A2 720/4885 |
| US-20160137672-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | GABRA1 2654/4885GABRB2 2115/4885CYP1A2 735/4885 |
| US-20120149743-A9 | Selenophene and Selenazole Carboxylic Acid Derivatives | DAO, DDO, SELENOI | GABRA1 1035/4885GABRB2 682/4885CYP1A2 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.